Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

NCT ID: NCT00902044

Last Updated: 2024-12-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-11
• Study Completion Date: 2032-07-31

Brief Summary

Patients have a type of cancer called sarcoma. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, patients are being asked to volunteer to take part in a gene transfer research study using special immune cells. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from diseases caused by germs or toxic substances. They work by binding those germs or substances, which stops them from growing or exerting their toxic effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers: they both have shown promise, but have not been strong enough to cure most patients. We have found from previous research that we can put a new gene into T cells that will make them recognize cancer cells and kill them. We now want to see if we can put a new gene in these cells that will let the T cells recognize and kill sarcoma cells. The new gene that we will put in makes an antibody specific for HER2 (Human Epidermal Growth Factor Receptor 2) that binds to sarcoma cells. In addition it contains CD28, which stimulated T cells and make them last longer. In other clinical studies using T cells, some investigators found that giving chemotherapy before the T cell infusion can improve the amount of time the T cells stay in the body and therefore the effect the T cells can have. Giving chemotherapy before a T cell infusion is called lymphodepletion since the chemotherapy is specifically chosen to decrease the number of lymphocytes in the body. Decreasing the number of patient's lymphocytes first should allow the T cells we infuse to expand and stay longer in your body, and potentially kill cancer cells more effectively. We will use fludarabine or the combination of cyclophosphamide and fludarabine as the chemotherapy agents for lymphodepletion. Cyclophosphamide and fludarabine are the chemotherapy agents most commonly used for lymphodepletion in immunotherapy clinical trials. The purpose of this study is to find the largest safe dose of chimeric T cells, and to see whether this therapy might help patients with sarcoma. Another purpose is to see if it is safe to give HER2-CD28 T cells after lymphodepleting chemotherapy.

Detailed Description

Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects of gene transfer.

When the patient is enrolled on this study, they will be assigned a dose of HER2-CD28 T cells. Depending on which dose level they are assigned, they will receive one of the following:

HER2-CD28 T cells and fludarabine (patient will receive fludarabine for 5 days followed by injection of HER2-CD28 T cells)

OR

HER2-CD28 T cells, fludarabine and cyclophosphamide (patient will receive fludarabine and cyclophosphamide for 2 days, fludarabine alone for an additional 3 days, and 2 days of rest before receiving the HER2-CD28 T cells.).

The HER2-CD28 T cells will be given into the vein through an IV line. The injection will take between 1 and 10 minutes. The patient will be followed in the clinic after the injection for 1 to 4 hours.

Each patient will be followed for 6 weeks after the T-cell infusion for evaluation of toxicity. They will have standard tests and procedures as well as research blood draws.

If the patient has stable disease (the tumor did not grow) or there is a reduction in the size of the tumor on imaging studies after the T-cell infusion, they can receive additional doses of the T cells at 6 to 12 weeks intervals. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Conditions

Sarcoma

Keywords

Refractory Sarcoma; Metastatic Sarcoma; Sarcoma; HER2-positive; Gene Therapy; HER2-specific T cells

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Autologous HER2-specific T cells

THIS ARM IS CLOSED

Dose Level 1: 1x10^4 cells/m2

Dose Level 2: 3x10^4 cells/m2

Dose Level 3: 1x10^5 cells/m2 (NOT BEING USED)

Dose Level 4: 3x10^5 cells/m2 (NOT BEING USED)

Dose Level 5: 1x10^6 cells/m2

Dose Level 6: 3x10^6 cells/m2

Dose Level 7: 1x10^7 cells/m2

Dose Level 8: 3x10^7 cells/m2

Dose Level 9: 1x10^8 cells/m2

Group Type: EXPERIMENTAL

Autologous HER2-specific T cells

Intervention Type: GENETIC

Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

HER2-specific T cells+fludarabine

Autologous HER2-specific T cells+fludarabine:

Dose Level 9A: fludarabine followed by 1x10^8 cells/m^2

Group Type: EXPERIMENTAL

Autologous HER2-specific T cells

Intervention Type: GENETIC

Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Fludarabine

Intervention Type: DRUG

Fludarabine will be administered for 5 days prior to the T cells

The dose:

>10 kg: 25 mg/m2/day;

<10 kg: 1 mg/kg/day IV over 30 minutes

HER2-specific T cells+fludarab.+cycloph.

Autologous HER2-specific T cells+fludarabine+cyclophosphamide:

Dose Level 9B: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2

Group Type: EXPERIMENTAL

Autologous HER2-specific T cells

Intervention Type: GENETIC

Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Fludarabine

Intervention Type: DRUG

Fludarabine will be administered for 5 days prior to the T cells

The dose:

>10 kg: 25 mg/m2/day;

<10 kg: 1 mg/kg/day IV over 30 minutes

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide will be administered for 2 days.

Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.

Cyclophosphamide Dose:

30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)

Fludarabine Dose:

>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes

CAR Positive cells

Dose Level 9C: fludarabine + cyclophosphamide followed by 1x10\^8 cells/m\^2 CAR positive cells/m\^2

Group Type: EXPERIMENTAL

Autologous HER2-specific T cells

Intervention Type: GENETIC

Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Fludarabine

Intervention Type: DRUG

Fludarabine will be administered for 5 days prior to the T cells

The dose:

>10 kg: 25 mg/m2/day;

<10 kg: 1 mg/kg/day IV over 30 minutes

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide will be administered for 2 days.

Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.

Cyclophosphamide Dose:

30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)

Fludarabine Dose:

>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes

Autologous CAR Positive T cells

Intervention Type: GENETIC

Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.

Interventions

Autologous HER2-specific T cells

Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Intervention Type: GENETIC

Fludarabine

Fludarabine will be administered for 5 days prior to the T cells

The dose:

>10 kg: 25 mg/m2/day;

<10 kg: 1 mg/kg/day IV over 30 minutes

Intervention Type: DRUG

Cyclophosphamide

Cyclophosphamide will be administered for 2 days.

Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.

Cyclophosphamide Dose:

30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)

Fludarabine Dose:

>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes

Intervention Type: DRUG

Autologous CAR Positive T cells

Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.

Intervention Type: GENETIC

Other Intervention Names

Fludara; Cytoxan

Eligibility Criteria

Inclusion Criteria

Procurement Eligibility:

1. Diagnosis of refractory HER2-positive sarcoma or metastatic HER2-positive osteosarcoma.

2. Karnofsky/Lansky score of 50 or greater

3. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

Treatment Eligibility:

1. Diagnosis of refractory HER2-positive sarcoma or metastatic HER2-positive sarcoma with disease progression after receiving at least one prior systemic therapy.

2. Recovered from acute toxic effects of all prior cytotoxic chemotherapy at least 4 weeks before entering this study. PD1/PDL1 inhibitors will be allowed to continue during treatment if medically indicated.

3. Normal ECHO (Left ventricular ejection fraction (LVEF) has to be within normal, institutional limits)

4. Life expectancy 6 weeks or greater

5. Karnofsky/Lansky score of 50 or greater

6. Bilirubin 3x or less, AST 3x or less, Serum creatinine 2x upper limit of normal or less, Hgb 7.0 g/dl or greater, WBC greater than 2,000/ul, ANC greater than 1,000/ul, platelets greater than 100,000/ul. Creatinine clearance is needed for patients with creatinine greater than 1.5 times upper limit of normal.

7. Pulse oximetry of 90% or greater on room air

8. Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. Male partner should use a condom

9. Available autologous transduced T lymphocytes with 15% or more expression of HER2 CAR as determined by flow-cytometry and killing of HER2-positive targets 20 % or greater in cytotoxicity assay.

10. Chest radiograph for baseline evaluation of lungs

11. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent

Exclusion Criteria

At time of Procurement:

1. Known HIV positivity

2. Severe previous toxicity from cyclophosphamide or fludarabine

At time of Treatment:

1. Severe intercurrent infection

2. Known HIV positivity

3. Pregnant or lactating

4. History of hypersensitivity reactions to murine protein-containing products

5. Severe previous toxicity from cyclophosphamide or fludarabine

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

Sponsor Role: collaborator

The Methodist Hospital Research Institute

OTHER

Sponsor Role: collaborator

Cancer Prevention Research Institute of Texas

OTHER

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Nabil Ahmed

Associate Professor, Pediatric Hematology Oncology, Center for Cell and Gene Therapy

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nabil M Ahmed, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine - Texas Children's Hospital

Locations

Houston Methodist Hospital

Houston, Texas, United States

Texas Children's Hospital

Houston, Texas, United States

Countries

United States

References

Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun;5(6):880-894. doi: 10.1038/s43018-024-00749-6. Epub 2024 Apr 24.

Reference Type: DERIVED

PMID: 38658775 (View on PubMed)

Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 Jul 15;11(1):3549. doi: 10.1038/s41467-020-17175-8.

Reference Type: DERIVED

PMID: 32669548 (View on PubMed)

Provided Documents

Document Type: Informed Consent Form

View Document

Other Identifiers

HEROS

Identifier Type: OTHER

Identifier Source: secondary_id

24489-HEROS

Identifier Type: -

Identifier Source: org_study_id